TLFA
MYGN icon

True Link Financial Advisors’s Myriad Genetics MYGN Stock Holding History

True Link Financial Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-23,611
Closed -$719K – 733
2021
Q1 		$719K Hold
23,611
– – 0.1% 85
2020
Q4 		$467K Buy
+23,611
New +$381K 0.07% 104

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

True Link Financial Advisors's MYGN Position: Q2 2021 in Review

True Link Financial Advisors sold out of Myriad Genetics (MYGN) in Q2 2021, closing a stake of 23,611 shares — an estimated $719K sold.

True Link Financial Advisors first reported a position in MYGN in Q4 2020 and held it in 2 quarters. The position peaked at $719K in Q1 2021. 201 funds tracked by Wall St. Rank hold MYGN as of Q2 2021.

  • True Link Financial Advisors reported no remaining Myriad Genetics position as of Q2 2021 after selling out during the quarter.
  • True Link Financial Advisors sold 23,611 Myriad Genetics shares in Q2 2021, an estimated $719K.
  • True Link Financial Advisors first reported a position in Myriad Genetics in Q4 2020 and held it in 2 quarters.
  • True Link Financial Advisors's Myriad Genetics position peaked at $719K in Q1 2021.
  • 201 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2021.

Based on True Link Financial Advisors's 13F filing for Q2 2021, filed 19 Aug 2021.